Cord Blood America, Inc. (CBAI) Cash Flow Statement

Consolidated Net Loss	100.13K
Shares issued (cancelled) relating to services, net
Shares issued to employees, directors and consultants
Amortization of loan discount	169.55K
Depreciation and amortization	275.69K
Stock Option Expense
Change in value of derivative liability	-228.4K
Bad Debt	17.25K
Start-up costs for Stellacure
Foreign currency translation
DWAC Settlement liabilities
Net Change in operating assets and liabilities
Net cash used in operating activities	512.32K
Purchase of property and equipment	0
Loans receivable issued to China Stem Cell
Loan receivable to ViviCells International, Inc.	24.32K
Loan Receivable issued to VidaPlus
Net cash used in investing activities	93.77K
Proceeds from issuance of common stock	0
Proceeds from the issuance of notes payable
Payments on advances from shareholders
Net cash provided by financing activities	-275K
Net Decrease in cash	331.09K
Cash balance at beginning of period	789.05K
Cash balance at end of period	1.12M
Cash paid for interest
Cash paid for income taxes
Acquisition of Neocells customer contracts as repayment on more receivable through foreclosure
Debt repaid through issuance of common stock

Entities mentioned with CBAI

View All Entities